There is emerging evidence that rhinitis frequently precedes the onset of asthmatic symptoms. The frequent association of rhinitis and asthma has led to the concept that these conditions are likely manifestations of the same disease. This hypothesis has important implications for both the diagnosis and the management of these common conditions. Unfortunately, there is little known regarding the risk factors responsible for the progression of rhinitis to asthma. The current treatment options can control symptoms but do not prevent or cure the disease. However, there is recent data supporting the notion that it is possible to prevent new asthma cases by modifying the immune response and clinical outcome with allergen immunotherapy. This review article evaluates the impact of rhinitis on the development of asthma, examines putative predictors for the progression of rhinitis to asthma, and reviews recent, promising literature suggesting that early treatment of allergic individuals with immunotherapy may aid in asthma prevention.
Get full access to this article
View all access options for this article.
References
1.
BousquetJ, Van CauwenbergeP, KhaltaevN; Aria Workshop Group of the World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol, 2001; 108(5 Suppl):S147–S334.
2.
TogiasA. Rhinitis and asthma: evidence for respiratory system integration. J Allergy Clin Immunol, 2003; 111:1171–1183.
3.
BousquetJ, VignolaAM, DemolyP. Links between rhinitis and asthma. Allergy, 2003; 58:691–706.
World Allergy Organization. Combined allergic rhinitis and asthma syndrome. http://www.worldallergy.org/professional/allergic_diseases_center/caras/airwayssynopsis.php.
8.
CustovicA, SimpsonBM, SimpsonA, KissenP, WoodcockA; for the NAC Manchester Asthma and Allergy Study Group. Effect of environmental manipulation in pregnancy and early life respiratory symptoms and atopy during first year of life: a randomized trial. Lancet, 2001; 358:188–193.
9.
PeatJK, MihrshahiS, KempA, MarksGB, ToveyER, WebbK, MellisCM, LeederSR. Three year outcomes of dietary fatty acid modification and house dust mite avoidance in the childhood asthma prevention study (CAPS). J Allergy Clin Immunol, 2004; 114:807–813.
10.
HorakF, MatthewsS, IhorstG, ArshadSH, FrischerT, KuehrJ, SchwiegerA, ForsterJ; SPACE study group. Effect of mite-impermeable encasings and an educational package on the development of allergies in a multinational randomized, controlled birth cohort study—24 months results of the Study of Prevention of Allergy in children in Europe. Clin Exp Allergy, 2004; 34:1220–1225.
CrimiN, PalermoF, OliveriR, VancheriC, DistefanoSM, PalermoB, PolosaR, MistrettaA. Influence of asthmatic and rhinitic symptomatology and duration on bronchial responsiveness to histamine. Int J Tiss React, 1987; IX(6 ): 515–520.
18.
BradleyBL, AzzawiM, JacobsonM, AssoufiB, CollinsJV, IraniAM, SchwartzLB, DurhamSR, JefferyPK, KayAB. Eosinophils, T lymphocytes, mast cells, neutrophils and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparisons with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol, 1991; 88:661–674.
19.
DjukanovicR, LaiCKW, WilsonJW, BrittenKM, WilsonSJ, RocheWR, HowarthPH, HolgateST. Bronchial mucosal manifestation of atopy: a comparison of markers of inflammation between atopic asthmatics, atopic non-asthmatics and healthy controls. Eur Respir J, 1992; 5:538–544.
20.
PolosaR, CiamarraI, ManganoG, ProsperiniG, PistorioMP, VancheriC, CrimiN. Bronchial hyperresponsiveness and airway inflammation markers in nonasthmatics with allergic rhinitis. Eur Respir J, 2000; 15:30–35.
21.
BramanSS, BarrowsAA, DeCotiisBA. Airway hyperresponsiveness in allergic rhinitis: a risk factor for asthma. Chest, 1987; 91:671–674.
22.
SparrowD, O’ConnorG, ColtonT, BarryCL, WeissST. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function: the Normative Aging Study. Am Rev Respir Dis, 1987; 135:1255–1260.
23.
HoppRJ, TownleyRG, BivenRE, BewtraAK, NairNM. The presence of airway reactivity before the development of asthma. Am Rev Respir Dis, 1990; 141:2–8.
24.
SettipaneRJ, HagyGW, SettipaneGA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc, 1994; 15:21–25.
25.
GuerraS, SherrillDL, MartinezFD, BarbeeRA. Rhinitis as an independent risk factor for adult-onset asthma. J Allergy Clin Immunol, 2002; 109:419–425.
26.
LeynaertB, NeukirchC, KonyS, GuénégouA, BousquetJ, AubierM, NeukirchF. Association between asthma and rhinitis according to atopic sensitization in a population-based study. J Allergy Clin Immunol, 2004; 113:86–93.
27.
HuovinenE, KaprioJ, LaitinenLA, KoskenvuoM. Incidence and prevalence of asthma among adult Finnish men and women of the Finnish Twin Cohort from 1975 to 1990 and their relation to hay fever and chronic bronchitis. Chest, 1999; 115:928–936.
28.
ShaabanR, ZureikM, SoussanD, NeukirchC, HeinrichJ, SunyerJ, WjstM, CerveriI, PinI, BousquetJ, JarvisD, BurneyPG, NeukirchF, LeynaertB. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet, 2008; 372:1049–1057.
29.
MollerC, DreborgS, FerdousiHA, HalkenS, H⊘stA, JacobsenL, KoivikkoA, KollerDY, NiggemannB, NorbergLA, UrbanekR, ValovirtaE, WahnU. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol, 2002; 109:251–256.
30.
PolosaR, Al-DelaimyWK, RussoC, PiccilloG, SarvaM. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res, 2005; 6:153–162.
31.
NiggemannB, JacobsenL, DreborgS, FerdousiHA, HalkenS, H⊘stA, KoivikkoA, KollerD, NorbergLA, UrbanekR, ValovirtaE, WahnU, MöllerC; PAT Investigator Group. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy, 2006; 61:853–857.
32.
JacobsenL, NiggemannB, DreborgS, FerdousiHA, HalkenS, HostA, KoivikkoA, NorbergLA, ValovirtaE, WahnU, MollerC (The PAT Investigator Group). Specific Immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT Study. Allergy, 2007; 62:943–948.
33.
Platts-MillsTAE, WheatleyL. The role of allergy and atopy in asthma. Curr Opin Pulm Med, 1996; 2:29–34.
34.
Platts-MillsTAE, deWeck AL. Dust mite allergens and asthma: a worldwide problem. J Allergy Clin Immunol, 1989; 83:416–427.
35.
SporikR, HolgateST, Platts-MillsTAE, CogswellJJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. N Engl J Med, 1990; 323:502–507.
36.
D’AmatoG, SpieksmaM, LiccardiG, JägerS, RussoM, Kontou-FiliK, NikkelsH, WüthrichB, BoniniS. Pollen-related allergy in Europe. Allergy, 1998; 53:567–578.
37.
SallustoF, CorintiS, PiniC, BioccaMM, BrunoG, DiFelice G. Parietaria judaica-specific T-cell clones from atopic patients: heterogeneity in restriction, Vb usage, and cytokine profile. J Allergy Clin Immunol, 1996; 97:627–637.
38.
VennA, LewisS, CooperM, HillJ, BrittonJ. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. BMJ, 1998; 316:1945–1946.
39.
MartinezFD, ClineM, BurrowsB. Increased incidence of asthma in children of smoking mothers. Pediatrics, 1992; 89:21–26.
40.
EhrlichRI, DuToit D, JordaanE, ZwarensteinM, PotterP, VolminkJA, WeinbergE. Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. Am J Respir Crit Care Med, 1996; 154:681–688.
41.
LuxAL, HendersonAJ, PocockSJ. Wheeze associated with prenatal tobacco smoke exposure: a prospective, longitudinal study. ALSPAC Study Team. Arch Dis Child, 2000; 83:307–312.
42.
ManninoDM, MoormanJE, KingsleyB, RoseD, RepaceJ. Health effects related to environmental tobacco smoke exposure in children in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med, 2001; 155:36–41.
43.
PolosaR, KnokeJD, RussoC, PiccilloG, CaponnettoP, SarvàM, ProiettiL, Al-DelaimyWK. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol, 2008; 121:1428–1434.
44.
PolosaR, SalviS, DiMaria GU. Allergic susceptibility associated with diesel exhaust particle exposure: clear as mud. Arch Environ Health, 2002; 57:188–193.
45.
Diaz-SanchezD, RumoldR, GongHJr. Challenge with environmental tobacco smoke exacerbates allergic airway disease in human beings. J Allergy Clin Immunol, 2006; 118:441–446.
46.
Platts-MillsTA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med, 2001; 164(8 Pt 2):S1–S5.
47.
PiccilloG, CaponnettoP, BartonS, RussoC, OriglioA, BonaccorsiA, Di MariaA, OliveriC, PolosaR. Changes in airway hyperresponsiveness following smoking cessation: comparisons between Mch and AMP. Respir Med, 2008; 102:256–265.
48.
CaponnettoP, PolosaR, BestD. Tobacco use cessation counseling of parents. Curr Opin Pediatr, 2008; 20:729–733.
49.
PolosaR. New frontiers in allergen immunotherapy for asthma. In: PolosaR, HolgateST, eds. Therapeutic strategies in asthma: current treatments. Oxford: Clinical Publishing, 2007, pp. 105–110.
50.
DesRoches A, ParadisL, MenardoJL, BougesS, DauresJP, BousquetJ. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol, 1997; 99:450–453.
51.
Purello-D’AmbrosioF, GangemiS, MerendinoRA, IsolaS, PuccinelliP, ParmianiS, RicciardiL. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy, 2001; 31:1295–1302.
52.
PajnoGB, BarberioG, DeLuca F, MorabitoL, ParmianiS. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy, 2001; 31:1392–1397.
53.
PolosaR, LiGotti F, ManganoG, PaolinoG, MastruzzoC, VancheriC, LisitanoN, CrimiN. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy, 2004; 59:1224–1228.
54.
NovembreE, GalliE, LandiF, CaffarelliC, PifferiM, DeMarco E, BurasteroSE, CaloriG, BenettiL, BonazzaP, PuccinelliP, ParmianiS, BernardiniR, VierucciA. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol, 2004; 114:851–857.
55.
MarognaM, TomassettiD, BernasconiA, ColomboF, MassoloA, BusincoAD, CanonicaGW, PassalacquaG, TripodiS. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol, 2008; 101:206–211.
56.
MilaniM, PecoraS, BurasteroS; EFESO Investigators Study Group. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin, 2008; 24:2719–2724.
57.
HolgateST, PolosaR. Treatment strategies for allergy and asthma. Nat Rev Immunol, 2008; 8:218–230.
58.
GuilbertTW, MorganWJ, ZeigerRS, MaugerDT, BoehmerSJ, SzeflerSJ, BacharierLB, LemanskeRFJr ., StrunkRC, AllenDB, BloombergGR, HeldtG, KrawiecM, LarsenG, LiuAH, ChinchilliVM, SorknessCA, TaussigLM, MartinezFD. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med, 2006; 354:1985–1997.
59.
BisgaardH, HermansenMN, LolandL, HalkjaerLB, BuchvaldF. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med, 2006; 354:1998–2005.
60.
MurrayCS, WoodcockA, LangleySJ, MorrisJ, CustovicA; IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet, 2006; 368:754–762.
61.
. Promoting tolerance to common allergens in high-risk children: Global Prevention of Asthma in Children (GPAC) Study. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00346398.
